Prepectoral breast reconstruction is an increasingly prevalent form of breast reconstruction. Prepectoral breast reconstruction was abandoned in the past due to various complications but has recently made a resurgence due to the development of acellular dermal matrices and innovative techniques. The purpose of this review article is to discuss the history, techniques, benefits, and potential complications of prepectoral breast reconstruction. The article also reviews current literature to evaluate published complication rates. Complications evaluated include infection (3.67%), wound dehiscence (2.10%), skin necrosis (3.67%), seroma (2.89%), hematoma (1.34%), implant loss (3.28%), return to the OR (6.15%), contracture (3.61%), and rippling (7.38%). In conclusion, prepectoral breast reconstruction is a reliable, safe, and aesthetically feasible method of breast reconstruction. With increasing interest in this technique, it is important that surgeons and patients are familiar with prepectoral reconstruction and this article aims at providing this information.
Macromastia—overgrowth of the female breast—is distressing and disabling, often starting in middle school and continuing into adulthood. Breast reduction is an effective treatment of symptoms of macromastia in adults, and its application in adolescents has been increasing. Special considerations within the adolescent population include interruption of age-appropriate activities, development of healthy body image/esteem, the connection to obesity, potential for postoperative recurrence/continued growth, the effect of surgery on future lactation and breast-feeding, and the adolescent's ability to participate in surgical decision-making (assent). This review highlights these issues and reviews breast reduction surgery outcomes and complications as they apply to the female adolescent. After reading this article, the reader should be able to identify adolescents who may be candidates for breast reduction surgery and have the information needed to counsel patients before their referral to a surgeon. [ Pediatr Ann . 2023;52(1):e31–e35.]
Purpose Breast conservation has become the mainstay of surgical management for early stage breast cancer. Large volume displacement oncoplastic surgery (LVOS) uses reconstructive mastopexy and breast reduction techniques to allow for larger oncologic resections while providing good aesthetic outcomes in a single operation. Oncoplastic surgery publications have recently increased by 220%, demonstrating the increasing popularity of this surgical technique, 2 and many of these studies have demonstrated excellent oncologic outcomes.4 To date, however, no study has used the most recent SSO/ASBrS/ASTRO surgical margin recommendations to assess oncoplastic surgery. 4 Recent SSO/ASBrS/ASTRO guidelines established no ink on tumor as an adequate margin for invasive breast cancer and at least 2mm as adequate margins for ductal carcinoma in situ. The purpose of this study was to investigate the surgical margin rates of LVOS using the new SSO/ASBrS/ASTRO guidelines. We presumed that under the newer, stricter guidelines, LVOS would have a higher positive margin rate than reported in the past literature. Methods: Our study consisted of two parts. First, a literature review to assess margin rates before the introduction of SSO/ASBrS/ASTRO guidelines was done using PRISMA guidelines with an international Pubmed search and reviewed by two blinded authors. The search included keywords such as “oncoplastic breast surgery,” “lumpectomy,” “partial mastectomy,” and “positive margins associated with breast surgery.” All articles either pertained to LVOS, standard lumpectomy (SL) or both. The inclusion criteria for our study included histology discrepancy, and new guideline margin status. From this, we determined the published positive margin for SL and LVOS. Second, we analyzed all LVOS performed at our institution since the adoption of the new SSO/ASBrS/ASTRO margin guidelines and compared these margin rates to the literature review outcomes using Z tests. Results: Our study consisted of 1702 patients. There were 847 patients in LVOS group and 855 patients in the SL group. Of the 45 papers evaluated, 34 were not included due to exclusion criteria (missing: new margin guidelines, histology, or margin status). The pre-guideline positive margin rate for LVOS was lower than with SL (12.51% vs. 20.4%, P-value <0.001). Of the 50 LVOS operations done at our institution since adoption of the SSO/ASBrS/ASTRO margin guidelines, no statistical difference in the positive margin rates was noted when compared to the literature rates (10% vs. 12.67% respectively, P-value 0.5796). Positive margin rates for LVOS at our institution were lower than SL margin rates reported in the literature (P-value 0.0358). Conclusions: This study demonstrates that even with the stricter margin SSO/ASBrS/ASTRO guidelines, LVOS still has a low positive margin rate comparable to pre-guideline literature reports. LVOS continues to have a significantly lower positive margin rate than SL. This is the first study to report margin rates for LVOS after the adoption of the SSO/ASBrS/ASTRO guidelines, and confirms the importance of LVOS in providing optimal oncologic outcomes for patient with large locally advanced breast cancer. Citation Format: Jonczyk MM, Patel K, Graham R, Naber S, Erban J, Chen L, Chatterjee A. Does large volume displacement oncoplastic surgery still offer an advantage of a low positive margin rate using the new SSO/ASBrS/ASTRO margin guidelines? [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-13-06.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.